UNSPSC 51451606: Triclabendazole

This classification denotes an antihelminthic agent with the molecular formula C14H9Cl3N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4784C8E03O, chemically known as 6-chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole but generally known as triclabendazole, which bears US NIH Compound Identifier 50248. European Medicines Agency schedules Triclabendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11267MIG.

UNSPSC 51451606 Triclabendazole, a Commodity code, does not reflect the pharmaceutical procurement activity documented in the recent state and local opportunities available for this code. The two opportunities indexed under this UNSPSC show no connection to triclabendazole, an antiparasitic agent used primarily in veterinary and niche human applications. Instead, the recent records document procurement of unrelated pharmaceuticals — doxycycline and ciprofloxacin antibiotics through a completed Illinois Department of Public Health piggyback award, and naloxone and drug deactivation systems through an open Seminole County, Florida competitive bid. The code appears to be a cataloging mismatch or legacy classification that does not align with current state and local pharmaceutical buying patterns for this specific commodity.

Given the absence of relevant recent activity under this code's actual scope, firms pursuing triclabendazole sales should verify the correct UNSPSC classification with target procurement offices or cooperative purchasing vehicles before building a pursuit strategy. The mismatch between the code name and the opportunities indexed to it signals either a data quality issue in the state and local sourcing infrastructure or minimal current demand for triclabendazole in public sector procurement, neither of which supports a pursue recommendation at this time.